Published in Am J Cardiol on August 15, 2005
Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol (2012) 0.95
Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol (2015) 0.80
Cerebral embolism from Libman-Sacks endocarditis. BMJ Case Rep (2011) 0.77
Rapidly progressive intracranial artery stenosis in primary antiphospholipid syndrome. Ann Clin Transl Neurol (2015) 0.75
"How many times must a man look up before he can really see the sky?" Rheumatic cardiovascular disease in the era of multimodality imaging. World J Methodol (2015) 0.75
Role of cardiovascular imaging in systemic autoimmune diseases. World J Cardiol (2010) 0.75
Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome. Clin Rheumatol (2008) 0.75
The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol (2015) 2.84
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum (2005) 2.39
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol (2012) 2.18
Autophagy in human health and disease. N Engl J Med (2013) 2.04
Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. Arthritis Care Res (Hoboken) (2013) 2.04
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
Complementary and alternative medicine in fibromyalgia: a practical clinical debate of agreements and contrasts. Clin Exp Rheumatol (2013) 1.98
Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: prevalence and clinical value. Autoimmunity (2008) 1.90
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant (2008) 1.77
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.76
Retracted The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest (2004) 1.68
Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci (2005) 1.63
Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. Rheumatology (Oxford) (2009) 1.60
The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum (2012) 1.50
Multicentre evaluation of IL Test Free PS: a fully automated assay to quantify free protein S. Thromb Haemost (2002) 1.49
TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci (2009) 1.47
The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev (2011) 1.47
Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol (2009) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol (2008) 1.43
Feet nailfold capillaroscopy is not useful to detect the typical scleroderma pattern. Clin Exp Rheumatol (2012) 1.39
Migraine during systemic lupus erythematosus: findings from brain single photon emission computed tomography. J Rheumatol (2006) 1.39
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis (2013) 1.37
New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis). Curr Opin Rheumatol (2004) 1.33
Retracted Drug-induced lupus erythematosus. Autoimmunity (2005) 1.31
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci (2007) 1.26
Primary and secondary autoimmune neutropenia. Arthritis Res Ther (2005) 1.25
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25
Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev (2011) 1.25
Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med (2006) 1.24
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev (2008) 1.20
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther (2006) 1.17
Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol (2005) 1.16
Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol (2005) 1.16
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.15
Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev (2010) 1.15
Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig (2012) 1.12
Environment and systemic lupus erythematosus: an overview. Autoimmunity (2005) 1.12
Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J Rheumatol (2004) 1.11
Anti-Mi-2 antibodies. Autoimmunity (2005) 1.10
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica (2003) 1.09
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol (2006) 1.09
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost (2006) 1.09
Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev (2012) 1.08
Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol (2006) 1.07
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol (2009) 1.06
Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly (2010) 1.06
Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial. J Cardiovasc Med (Hagerstown) (2011) 1.05
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol (2013) 1.05
Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev (2008) 1.05
Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev (2008) 1.05
Is atherosclerosis an autoimmune disease? BMC Med (2014) 1.05
Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther (2006) 1.04
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev (2008) 1.04
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) (2011) 1.04
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) (2010) 1.04
Calcium deposition and associated chronic diseases (atherosclerosis, diffuse idiopathic skeletal hyperostosis, and others). Rheum Dis Clin North Am (2006) 1.04
The genetics of fibromyalgia syndrome. Pharmacogenomics (2007) 1.04
Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum (2007) 1.03
Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev (2011) 1.03
Estrogens in pregnancy and systemic lupus erythematosus. Ann N Y Acad Sci (2006) 1.02
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol (2012) 1.02
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One (2013) 1.01
Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev (2007) 1.00
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis (2011) 1.00
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol (2011) 0.99
SERPINB3, apoptosis and autoimmunity. Autoimmun Rev (2009) 0.99
Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev (2006) 0.98